Clinical trials: Chemotherapy-induced Anemia
Anemia
The Duration Study
The purpose of this study is to compare the efficacy of epoetin alfa (PROCRIT®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (PROCRIT®) treatment in patients with cancer who are anemic.
- Trial name
- NCT00210730
- Testing
- epoetin alfa
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Anemia, Non-Myeloid Malignancies
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
- Trial name
- NCT00110955
- Testing
- Darbepoetin alfa
- Volunteers
- 391 people
- Sponsor
- Amgen
Chemotherapy Induced Anemia
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
- Trial name
- NCT00144495
- Testing
- recombinant human erythropoietin
- Volunteers
- 104 people
- Sponsor
- Chugai Pharmaceutical
Chemotherapy Induced Anemia
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.
- Trial name
- NCT04076943
- Testing
- Roxadustat
- Where
- 15 sites in United States
- Volunteers
- 92 people
- Sponsor
- Kyntra Bio
Chemotherapy-induced Symptomatic Anaemia, Solid Tumours
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
- Conditions
- Chemotherapy-induced Symptomatic Anaemia, Solid Tumours, Malignant Lymphomas, Multiple Myeloma
- Trial name
- NCT01626547
- Where
- 39 sites in Germany
- Volunteers
- 291 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Trial name
- NCT01297543
- Testing
- human myeloid progenitor cells, G-CSF
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellerant Therapeutics
Chemotherapy-induced Anemia, Non-myeloid Malignancies
Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies
This study employs a multicenter, randomized, open-label, positive drug-controlled, multiple ascending dose clinical trial design to comprehensively evaluate the safety, tolerability, immunogenicity, and pharmacokinetic…
- Trial name
- NCT06854276
- Testing
- SSS06, rhEPO
- Volunteers
- 80 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Anemia
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.
- Trial name
- NCT02767765
- Testing
- r-HuEPO
- Where
- 7 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
Chemotherapy Induced Anemia, Cancer
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.
- Trial name
- NCT00272662
- Testing
- peginesatide
- Where
- 10 sites in Czechia, Poland and 1 more
- Volunteers
- 60 people
- Sponsor
- Affymax
Anemia, Non-Myeloid Malignancies
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
The purpose of this study is to compare the effect of darbepoetin alfa administered in a weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
- Conditions
- Anemia, Non-Myeloid Malignancies, Cancer
- Trial name
- NCT00111462
- Testing
- Darbepoetin alfa
- Sponsor
- Amgen
Myelodysplastic Syndromes (MDS)
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS.
- Trial name
- NCT03593915
- Testing
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cancer, Anemia
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
The purpose of this study is to determine the effectiveness and safety of PROCRIT (Epoetin alfa) at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb) of 12 g/dL (Initiation Phase), followed by a…
- Trial name
- NCT00338416
- Testing
- Epoetin alfa
- Volunteers
- 115 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chemotherapy Induced Anemia
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
The main goal of this study is to evaluate the efficacy of roxadustat for treatment of anemia in participants with non-myeloid malignancies receiving multi-cycle treatments of myelosuppressive chemotherapy.
- Trial name
- NCT05301517
- Testing
- SEPO®, Roxadustat
- Where
- 45 sites in China
- Volunteers
- 159 people
- Sponsor
- Kyntra Bio
Non-hematological Malignancies
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
- Trial name
- PK-CIA-04 (NCT01213979)
- Testing
- 500 mg iron isomaltoside 1000, 1000 mg iron isomaltoside 1000
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Anemia of Chronic Kidney Disease, Chemotherapy Effect
Desidustat in the Treatment of Chemotherapy Induced Anemia
This is a Phase 1, Open-label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for treatment of anemia in patients receiving chemotherapy.
- Trial name
- NCT04667533
- Testing
- Desidustat
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Anemia, Cancer
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) in the treatment of anemia in subjects with…
- Trial name
- NCT00144131
- Testing
- Aranesp®
- Volunteers
- 750 people
- Sponsor
- Amgen
Chemotherapy Induced Anemia
Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept…
- Trial name
- NCT00931606
- Testing
- Sotatercept
- Where
- 35 sites in United States, Russia
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC